The mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) supports intravenous self-administration and induces conditioned place preference in the rat

European Journal of Pharmacology

Volumn 607, Issue 1-3, 2009, Pages 114-120

  van der Kam, Elizabeth L ^b   De Vry, Jean ^a   Tzschentke, Thomas M ^a  

^a GRÜNENTHAL GMBH   (Germany)

^b Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

Drug abuse; Heroin; Ketamine; Metabotropic glutamate receptor; Reinforcement; Reward

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; DIAMORPHINE; KETAMINE; SODIUM CHLORIDE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL PROTOCOL; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REINFORCEMENT; REWARD;

ANIMALS; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; HEROIN; INFUSIONS, INTRAVENOUS; KETAMINE; MALE; PYRIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, METABOTROPIC GLUTAMATE; REINFORCEMENT SCHEDULE; REWARD; SELF ADMINISTRATION; TIME FACTORS;

EID: 62549140970     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.01.049     Document Type: Article

References (43)

1. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., Nagren K., Vilkman H., Gustafsson L.L., Syvalahti E., and Hietala J. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 182 (2005) 375-383
2. Aoki T., Narita M., Shibasaki M., and Suzuki T. Metabotropic glutamate receptor 5 localized in the limbic forebrain is critical for the devlopment of morphine-induced rewarding effect in mice. Eur. J. Neurosci. 20 (2004) 1633-1638
3. Backstrom P., and Hyytia P. Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine-seeking. NeuroPsychopharmacology 31 (2006) 778-786
4. Besheer J., Stevenson R.A., and Hodge C.W. mGlu5 receptors are involved in the discriminative stimulus effects of self-administered ethanol in rats. Eur. J. Pharmacol. 551 (2006) 71-75
5. Bespalov A.Y., Dravolina O.A., Sukhanov I., Zakharova E., Blokhina E., Zvartau E., Danysz W., van Heeke G., and Markou A. Metabotropic glutamate receptor (mGlu5 receptor) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49 (2005) 167-178
6. Cunningham C.L., Niehus J.S., and Noble D. Species difference in sensitivity to ethanol's hedonic effects. Alcohol. 10 (1993) 97-102
7. Cunningham C.L., Clemans J.M., and Fidler T.L. Injection timing determines whether intragastric ethanol produces conditioned place preference or aversion in mice. Pharmacol. Biochem. Behav. 72 (2002) 659-668
8. Cunningham C.L., Patel P., and Milner L. Spatial location is critical for conditioning place preference with visual but not tactile stimuli. Behav. Neurosci. 120 (2006) 1115-1132
9. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
10. Golembiowska K., Konieczny J., Wolfarth S., and Ossowska K. Neuroprotective action of MPEP, a selective mGlu5 receptor antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats. Neuropharmacology 45 (2003) 484-492
11. Herzig V., Capuani E.M.I., Kovar K.A., and Schmidt W.J. Effects of MPEP on expression of food-, MDMA- or amphetamine-conditioned place preference in rats. Addict. Biol. 10 (2005) 243-249
12. Herzig V., and Schmidt W.J. Effects of MPEP on locomotion, sensitzation and conditioned rewards induced by cocaine or morphine. Neuropharmacology 47 (2004) 973-984
13. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., and Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29 (2004) 1259-1269
14. Kenny P.J., Boutrel B., Gasparini F., Koob G.F., and Markou A. Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing barain reward function in rats. Psychopharmacology (Berl) 179 (2005) 247-254
15. Kenny P.J., and Markou A. The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol. Sci. 25 (2004) 265-272
16. Kuhn R., Pagano A., Stoehr N., Vranesic I., Flor P.J., Lingenhohl K., Spooren W., Gentsch C., Vassout A., Pilc A., and Gasparini F. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. Amino Acids 23 (2002) 207-211
17. Le Foll B., and Goldberg S.R. Nicotine induced conditioned place preference over a large range of doses in rats. Psychopharmacology (Berl) 178 (2005) 481-491
18. Lea I.V.P.M., and Faden A.I. Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev. 12 (2006) 149-166
19. Lee B., Platt D.M., Rowlett J.K., Adewale A.S., and Spealman R.D. Attenuation of behavioural effects of cocaine by the metabotrobic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in squirrel monkeys: comparison wirh dizocilpine. J. Pharmacol. Exp. Ther. 312 (2005) 1232-1240
20. Leri F., Flores J., Rajabi H., and Stewart J. Effects of cocaine in rats exposed to heroin. Neuropsychopharmacology 28 (2003) 2102-2116
21. Liechti M.E., and Markou A. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur. J. Pharmacol. 554 (2007) 164-174
22. Magalas Z., De Vry J., and Tzschentke T.M. The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur. J. Pharmacol. 528 (2005) 103-109
23. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17 (1997) 2921-2927
24. O'Leary D.M., Movsesyan V., Vicini S., and Faden A.I. Selective mGlu5 receptor antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131 (2000) 1429-1437
25. Olive M.F., McGeehan A.J., Kinder J.R., McMahon T., Hodge C.W., Janak P.H., and Messing R.O. The mGlu5 receptor antagonist 6-methyl-2-(phenylethynyl)pyridine decreases ethanol consumption via a protein kinase C epsilon-dependent mechanism. Mol. Pharmacol. 67 (2005) 349-355
26. Paterson N.E., and Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) 179 (2005) 255-261
27. Paterson N.E., Semenova S., Gasparini F., and Markou A. The mGlu5 receptor antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) 167 (2003) 257-264
28. Popik P., and Wrobel M. Morphine conditioned reward is inhibited by MPEP, the mGlu5 receptor antagonist. Neuropharmacology 43 (2002) 1210-1217
29. Schenk S., and Partridge B. Sensitization to cocaine's reinforcing effects produced by various cocaine pretreatment regimens in rats. Pharmacol. Biochem. Behav. 66 (2000) 765-770
30. Schroeder J.P., Overstreet D.H., and Hodge C.W. The mGlu5 receptor antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats. Psychopharmacology (Berl) 179 (2005) 262-270
31. Schwartz R.H. Adolescent abuse of dextromethorphan. Clin. Pediatr. (Phila) 44 (2005) 565-568
32. Shalev U., Morales M., Hope B., Yap J., and Shaham Y. Time-dependent changes in extinction behavior and stress-induced reinstatement of drug seeking following withdrawal from heroin in rats. Psychopharmacology (Berl) 156 (2001) 98-107
33. Shalev U., Grimm J.W., and Shaham Y. Neurobiology of relapse to heroin and cocaine seeking: a review. Pharmacol. Rev. 54 (2002) 1-42
34. Skolnick P., Layer R.T., Popik P., Nowak G., and Paul I.A. Adaptation of the N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29 (1996) 23-26
35. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
36. Tzschentke T.M. Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology (Berl) 172 (2004) 58-67
37. Tzschentke T.M., Bruckmann W., and Friderichs E. Lack of sensitization during place conditioning in rats is consistent with the low abuse potential of tramadol. Neurosci. Lett. 329 (2002) 25-28
38. Van der Kam E.L., De Vry J., and Tzschentke T.M. Effect of 2-methyl-6-(phenylethynyl)pyridine on intravenous self-administration of ketamine and heroin in the rat. Beh. Pharmacology 18 8 (2007) 717-724
39. Van der Kam, E.L., De Vry, J., Tzschentke, T.M., in press. 2-Methyl-6(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur. J. Pharmacol.
40. Vanderschuren L.J., Schoffelmeer A.N., Mulder A.H., and De Vries T.J. Dizocilpine (MK801): use or abuse?. Trends Pharmacol. Sci. 19 (1998) 79-81
41. Verma A., and Moghaddam B. NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J. Neurosci. 16 (1996) 373-379
42. Vezina P. Sensitization of midbrain dopaminergic neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci. Biobehav. Rev. 27 (2004) 827-839
43. Wolff K., and Winstock A.R. Ketamine: from medicine to misuse. CNS Drugs 20 (2006) 199-218